Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Squamous Cell
  • Esophageal Neoplasms

abstract

  • Despite potential anti-tumor activity of this combination in patients with advanced esophageal cancer, further development is not warranted, given the severe toxicity, especially myalgias, that were seen.

publication date

  • October 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1007/s00280-008-0677-y

PubMed ID

  • 18270704

Additional Document Info

start page

  • 875

end page

  • 80

volume

  • 62

number

  • 5